Taipan Members Club  
World Investor
October 2000


Current IssueHotlineMember Services

     

Prepare for profits:
Massive U.S. rally imminent

by James Passin

Last year, I articulated a "King of the Carnival" thesis in Taipan. According to this view, the U.S. equity bubble was a reincarnation of the ancient Carnival, a celebratory frenzy in which normal laws were turned upside down and the village idiot was named King of the Carnival. Consequently, I recommended adopting an extremely cautious, trading-oriented strategy towards U.S. equities in Q4 1999.

In Q1 2000 issues of Taipan, I refined this skeptical view of U.S. tech stocks with the "Year of the Dragon" thesis. According to the Chinese astrological calendar, "Dragon years often give rise to celebrations or festivals. These years are meant for those who dream of vast success and brilliant victory... Because of the essentially mythical nature of dragons, any gains reaped during this year may prove to be fleeting or largely unreal."

Consequently, I downgraded all U.S.-correlated recommendations to Holds in the April 2000 issue of Taipan.

Immediately following the publication of my article, U.S. tech stocks collapsed, the outrageous paper gains enjoyed by dot-com shareholders and leveraged daytraders vanished, and the King of the Carnival was burned in effigy. While most investors are still hemorrhaging from the April-May bloodbath, Taipan subscribers are raking in profits: my Taipan stock recommendations are up an average 68% year-to-date.

Based on my technical view of the U.S. market, I expect a massive and imminent rally in our U.S.-correlated positions. I recommend unloading selected positions into this rally.

King of the Carnival
There's one single indicator of market health that has worked for over 100 years: the Utility Index. The Utility Index has never hit a record high immediately in front of a bear market. There's at least a 4-7 month lag between peaks in the Utility Index and peaks in the Dow.

The Utility Index is currently trading at record highs. This is an unequivocally bullish sign for the broader market. Furthermore, over the last two decades, the Utility Index has tended to exhibit 14-16 month cycles. In other words, trends in the Utility Index tend to last for at least 14-16 months. The current bullish trend in the Utilities began in December 1999. There's a lot of time left for further strength in the Utility Index.

Wiseguys will tell you that the Utility Index doesn't matter anymore. Utilities are driven by electricity deregulation, not interest rate expectations. Sure. I'm delighted that market gurus despise one of the oldest and most reliable of technical indicators. If everybody watched the Utility Index like a hawk, it would have absolutely no predictive value.

The strength in the Utility Index and weakness in the XAU gold share index suggests that long-term interest rates will continue to decline (without undercutting the dollar). Since fiscal and monetary conditions are tight, this should come as no surprise. The Fed may have to cut rates next year.

The immediate beneficiary of a radical shift in interest rate expectations will be rate-sensitive sectors, including insurance. I am, therefore, building up positions in small-cap insurance companies that have large portfolios of
government bonds. In general, companies with crushing levels of bank debt should also benefit. I expect to cover some low-risk/high-return plays on a radical shift in interest rate expectations in future issues of Taipan.

While everything is likely to bounce sharply in the fall, be careful with broken Internet stocks. I expect a massive dead cat bounce in marginal dot-com stories — followed by the mother of all tax loss selling seasons in October/November. New themes will carry the market in 2001. I believe these themes will include agbiotech, nanotechnology, and e-logistics. The biggest risks to short-term U.S. market stability are the (unsustainable) leadership of hyped fiber optic bubble stocks (the only fiber optic stock I like is ECIL, the parent company of ECTX) and, as Chris DeHaemer has advised me, the imminent lockup expiration of 2.4 billion shares in September and October.

Let winners ride — for now
Avant Immunotherapeutics (AVAN:NASDAQ) and Xoma (XOMA:NASDAQ), my two biotech recommendations, are up 288% and 300% year-to-date, respectively. I currently rate XOMA a "hold." I upgraded AVAN to "buy" when it dipped to US$7. Both emerging biotech companies are enjoying some institutional support and a favorable psychological environment for biotech (when I initiated coverage on AVAN, it traded around US$2 per share under the ticker symbol TCEL; when I first started writing about XOMA, it traded at US$4.50 per share and was utterly ignored by institutions). I want to have some exposure to biotech; however, I don't want to pay up for highly speculative paper. I recommend holding onto both XOMA and AVAN for further gains. I also recommend taking some profits on any massive news-triggered re-rating (small cap biotechs always seem to give you a second chance to get on board).

But the real opportunity is agricultural biotech. Hysteria regarding so-called "genetically modified foods" is creating a once-in-a-lifetime opportunity to buy high quality agbio companies at ludicrously depressed valuations. I will be discussing my outlook for agbio at the Agora Wealth Symposium 2000 in Las Vegas, as well as in future issues of Taipan.

Nice place to visit
The New Zealand equity market is performing miserably. Stock prices are weak, while the currency is tottering. The new Socialist government has hiked personal income tax rates, empowered the unions, and threatens the economy with even more destructive policies.

There is an outside chance that a vicious circle could emerge in which the socialist government creates such dire economic conditions that the public backs even more extreme socialistic legislation, leading to even greater economic destruction.

Coincident with the destructive policy changes of the new government is the "double dip" in Southeast Asia. Thailand and South Korea are experiencing post-Asian crisis-restructuring hangovers that are hurting New Zealand exports. Japan's economy has also failed (so far) to come back from the dead. New Zealand needs a Pan-Asian boom to ramp up its exports.

As an agriculture- and basic industry-driven export economy, New Zealand is not directly benefiting from the global technology boom. While the genomics revolution offers the potential for countries like New Zealand to convert their sleepy, capital intensive industries (wool, fish, wine, lamb, etc.) into value-added, high tech, cash-generating powerhouses, the New Zealanders unfortunately share the biotech phobia of Australians, the British, and Continental Europeans.

My bullish call on New Zealand stocks was incorrect. My Kiwi recommendations are flat since I initiated coverage. However, there remains tremendous value in specific Kiwi stocks, including Restaurant Brands (RBD:NZSE) and Fisher & Paykel (FAP:NZSE). RBD has an estimated 2000 dividend yield of 14% and a P/E ratio of 6! Its 98% market share of takeaway fried chicken should mitigate the impact of any economic downturn on the company's earnings. Despite my bleak view on New Zealand, the eventual Pan-Asian economic recovery should trigger a modest rebound in New Zealand stocks.

More upside for Russia
Lukoil Preferred ADR (LUKPY:OTC) has rallied 270% to US$24.00 since I initiated coverage in the November 1999 issue of Taipanbefore dividends! The 1999 cash dividend of US$1.216 per ADR, which was paid on April 17, 2000 to ADR holders of record, equated to an 18% dividend yield vs. our recommended entry price.

The formula for comparing Lukoil Preferred ADR (LUKPY:OTC) to Lukoil common ADR (LUKOY:OTC) is 2 LUKPY = 1 LUKOY. You need to multiply LUKPY's price by 2 to compare it to LUKOY. LUKPY * 2 = US$48. LUKOY is currently trading at US$64. This means the current discount between Lukoil preferred and Lukoil common is 25%.

When I recommended LUKPY, the discount between preferred and common shares was a ridiculous 60%. As I predicted, the discount contracted as irrational Russophobia dissipated. While the discount has experienced a massive one-time contraction, there is still upside leverage to the preferred. If LUKOY rises 50% and the discount contracts by half to 12.5%, LUKPY would rally to US$42ñ75% above current levels. In addition, the preferred is likely to continue paying out superior cash dividends. 1H FY 00 financial results at the holding company level implies a fat US$2 per ADR dividend to preferred ADR holders.

The only big downside in owning the preferred instead of the common is the lack of voting rights. But in Russia voting rights mean almost nothing. Furthermore, the preferred stock will be converted into de facto common stock if Lukoil neglects to pay 10% of holding company operating profits to preferred shareholders.

There is a rumor that Lukoil management has been accumulating preferred shares. This might sound bullish, but you have to remember this is Russia: if Lukoil insiders control a supermajority of preferred stock, they could force a conversion of preferred into common at unfavorable terms. On the other hand, management may be buying to enrich their personal accounts with large preferred dividends.

I don't have enough space to reiterate the entire Lukoil story, but there is still tremendous value in the stock. At current levels, Lukoil is trading at 4x earnings — and remains one of the world's top ten oil companies in terms of reserves, production, and refining capacity.

I recommend that LUKPY investors hold onto their ADRs for further gains. I would recommend switching from LUKPY to LUKOY if the discount shrinks below 10%.

Throwing in the towel
Enough is enough. Exponent (EXPO:NASDAQ) is dirt cheap on any metric, with a solid balance sheet and a strong franchise. Earnings are finally growing. But the stock has gone nowhere for years. Since EXPO is in a low-margin, capital-intensive business, I have doubts about the sustainability of current earnings growth momentum. Sell Exponent (EXPO:NASDAQ).


James Passin manages the Firebird Global Small Caps Fund for Firebird Management and is a Contributing Editor to Taipan. Several funds managed by Firebird are currently shareholders in Lukoil and Lukoil Preferred. Passin's fund is currently a shareholder in ECIL and ECTX. The views expressed are strickly Mr. Passin's and not necessarily those of Firebird Management or Taipan.




© Copyright by Agora Taipan, LLC • 808 Saint Paul Street, Baltimore, MD 21202 USA.
Site Design, Development & Hosting by e.magination network, llc.